Total Payments
$21,105
2024 Payments
$4,994
Companies
34
Transactions
966
Medicare Patients
5,711
Medicare Billing
$8.2M
Payment Breakdown by Category
Food & Beverage$19,761 (93.6%)
Other$1,200 (5.7%)
Education$143.41 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $19,761 | 960 | 93.6% |
| Honoraria | $1,200 | 1 | 5.7% |
| Education | $143.41 | 5 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $3,941 | 216 | $0 (2024) |
| ABBVIE INC. | $3,550 | 169 | $0 (2024) |
| Janssen Biotech, Inc. | $2,676 | 177 | $0 (2024) |
| Horizon Therapeutics plc | $2,302 | 34 | $0 (2023) |
| GlaxoSmithKline, LLC. | $1,457 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,344 | 82 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,149 | 30 | $0 (2024) |
| Lilly USA, LLC | $612.90 | 21 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $591.26 | 37 | $0 (2024) |
| Genentech USA, Inc. | $523.44 | 29 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,994 | 210 | ABBVIE INC. ($1,107) |
| 2023 | $3,786 | 168 | Janssen Biotech, Inc. ($554.29) |
| 2022 | $3,833 | 193 | ABBVIE INC. ($914.82) |
| 2021 | $3,858 | 202 | Amgen Inc. ($837.55) |
| 2020 | $4,294 | 176 | Horizon Therapeutics plc ($1,559) |
| 2019 | $339.68 | 17 | AbbVie, Inc. ($117.16) |
All Payment Transactions
966 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $7.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: Immunology | ||||||
| 12/19/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $6.52 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $12.58 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $23.61 | General |
| Category: Immunology | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/10/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $21.43 | General |
| 12/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $7.59 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $32.44 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Inflammation | ||||||
| 12/03/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Dermatology | ||||||
| 11/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $9.73 | General |
| Category: Dermatology | ||||||
| 11/19/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $6.87 | General |
| Category: Inflammation | ||||||
| 11/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $108.15 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Inflammation/Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,620 | 110,698 | $5.9M | $2.6M |
| 2022 | 24 | 1,745 | 137,003 | $5.6M | $2.3M |
| 2021 | 21 | 1,424 | 132,832 | $5.1M | $2.3M |
| 2020 | 20 | 922 | 65,433 | $2.0M | $990,975 |
Total Patients
5,711
Total Services
445,966
Medicare Billing
$8.2M
Procedure Codes
87
All Medicare Procedures & Services
87 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 43 | 10,389 | $1.4M | $658,909 | 48.8% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 55 | 17,325 | $1.2M | $578,885 | 46.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 199 | 15,660 | $469,800 | $283,601 | 60.4% |
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2023 | 11 | 2,200 | $396,000 | $241,793 | 61.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 52 | 22,050 | $882,000 | $227,472 | 25.8% |
| J0490 | Injection, belimumab, 10 mg | Office | 2023 | 12 | 3,841 | $307,280 | $153,308 | 49.9% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 17 | 24,800 | $222,160 | $116,415 | 52.4% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 40 | 4,140 | $538,200 | $106,300 | 19.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 228 | 693 | $207,900 | $76,578 | 36.8% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 16 | 7,560 | $108,032 | $60,321 | 55.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 185 | 349 | $69,800 | $28,562 | 40.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 131 | 186 | $23,250 | $11,573 | 49.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 97 | 407 | $24,420 | $9,652 | 39.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 54 | 54 | $13,500 | $7,185 | 53.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 66 | 304 | $18,240 | $3,890 | 21.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 218 | 324 | $16,200 | $3,732 | 23.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 12 | 15 | $2,250 | $697.11 | 31.0% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 61 | 79 | $1,580 | $669.60 | 42.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 53 | 131 | $2,620 | $556.24 | 21.2% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 11 | 55 | $3,850 | $314.33 | 8.2% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 47 | 123 | $1,230 | $100.04 | 8.1% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 12 | 13 | $130.00 | $77.41 | 59.5% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 64 | 18,250 | $1.3M | $632,586 | 48.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 77 | 32,253 | $1.3M | $381,988 | 29.6% |
| J9312 | Injection, rituximab, 10 mg | Office | 2022 | 34 | 4,600 | $598,000 | $306,021 | 51.2% |
About Dr. Yi Li, M.D
Dr. Yi Li, M.D is a Internal Medicine healthcare provider based in Bakersfield, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2013. The National Provider Identifier (NPI) number assigned to this provider is 1730525999.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yi Li, M.D has received a total of $21,105 in payments from pharmaceutical and medical device companies, with $4,994 received in 2024. These payments were reported across 966 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($19,761).
As a Medicare-enrolled provider, Li has provided services to 5,711 Medicare beneficiaries, totaling 445,966 services with total Medicare billing of $8.2M. Data is available for 4 years (2020–2023), covering 87 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Bakersfield, CA
- Active Since 05/15/2013
- Last Updated 05/12/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1730525999
Products in Payments
- KRYSTEXXA (Biological) $2,470
- RINVOQ (Biological) $2,384
- Enbrel (Biological) $2,092
- BENLYSTA (Biological) $1,457
- TREMFYA (Drug) $1,446
- SIMPONI ARIA (Biological) $1,005
- EVENITY (Biological) $863.80
- COSENTYX (Drug) $827.95
- SKYRIZI (Biological) $809.17
- SAPHNELO (Biological) $793.55
- TALTZ (Drug) $612.90
- REMICADE (Biological) $607.25
- ORENCIA (Biological) $591.26
- COSENTYX (Biological) $515.88
- Otezla (Drug) $428.63
- PURIFIED CORTROPHIN GEL (Drug) $415.82
- Rituxan (Biological) $414.83
- ACTHAR (Biological) $406.17
- LUPKYNIS (Drug) $371.38
- XELJANZ (Drug) $202.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Bakersfield
Franco Felizarta, Md, MD
Internal Medicine — Payments: $1.3M
Internal Medicine $1.3M
Dr. Soham Shah, M.d, M.D
Internal Medicine — Payments: $843,865
Internal Medicine $843,865
Dr. Hashim Kazmi, Md, MD
Internal Medicine — Payments: $122,044
Internal Medicine $122,044
Dr. Jeffrey Bacon, D.o, D.O
Internal Medicine — Payments: $108,805
Internal Medicine $108,805
Gurjit Singh, M.d, M.D
Internal Medicine — Payments: $54,630
Internal Medicine $54,630
Dr. Carlos Alvarez, Md, MD
Internal Medicine — Payments: $26,676
Internal Medicine $26,676